CN108349972B - 用于治疗呼吸疾病的jak激酶抑制剂化合物 - Google Patents

用于治疗呼吸疾病的jak激酶抑制剂化合物 Download PDF

Info

Publication number
CN108349972B
CN108349972B CN201680063886.1A CN201680063886A CN108349972B CN 108349972 B CN108349972 B CN 108349972B CN 201680063886 A CN201680063886 A CN 201680063886A CN 108349972 B CN108349972 B CN 108349972B
Authority
CN
China
Prior art keywords
alkyl
compound
ethyl
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680063886.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN108349972A (zh
Inventor
保罗·R·法特里
约翰·R·雅各布森
安妮-玛丽·博索莱伊
加里·E·L·勃兰特
梅丽莎·弗勒里
姜岚
卡梅伦·史密斯
史蒂文·D·E·沙利文
洛里·琼·范奥登
皮埃尔-让·科尔松
吉恩·蒂莫西·法斯
米罗斯拉夫·拉普塔
诺亚·本杰明
马尔塔·达布罗斯
文卡特·R·萨兰迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Theravance Biopharma R&D IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D IP LLC filed Critical Theravance Biopharma R&D IP LLC
Publication of CN108349972A publication Critical patent/CN108349972A/zh
Application granted granted Critical
Publication of CN108349972B publication Critical patent/CN108349972B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680063886.1A 2015-11-03 2016-11-02 用于治疗呼吸疾病的jak激酶抑制剂化合物 Expired - Fee Related CN108349972B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250113P 2015-11-03 2015-11-03
US62/250,113 2015-11-03
PCT/US2016/059999 WO2017079205A1 (en) 2015-11-03 2016-11-02 Jak kinase inhibitor compounds for treatment of respiratory disease

Publications (2)

Publication Number Publication Date
CN108349972A CN108349972A (zh) 2018-07-31
CN108349972B true CN108349972B (zh) 2021-06-08

Family

ID=57442794

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063886.1A Expired - Fee Related CN108349972B (zh) 2015-11-03 2016-11-02 用于治疗呼吸疾病的jak激酶抑制剂化合物

Country Status (22)

Country Link
US (6) US10100049B2 (enExample)
EP (1) EP3371186A1 (enExample)
JP (1) JP6800969B2 (enExample)
KR (1) KR20180073687A (enExample)
CN (1) CN108349972B (enExample)
AU (1) AU2016350816B2 (enExample)
BR (1) BR112018008966B1 (enExample)
CA (1) CA3001542C (enExample)
CL (1) CL2018001145A1 (enExample)
CO (1) CO2018005640A2 (enExample)
EA (1) EA034914B1 (enExample)
HK (1) HK1252685A1 (enExample)
IL (1) IL258772B (enExample)
MX (1) MX374605B (enExample)
MY (1) MY195427A (enExample)
NZ (1) NZ741737A (enExample)
PH (1) PH12018500828B1 (enExample)
SA (1) SA518391470B1 (enExample)
TW (1) TWI710560B (enExample)
UA (1) UA123633C2 (enExample)
WO (1) WO2017079205A1 (enExample)
ZA (1) ZA201802496B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180073687A (ko) 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
AU2018231035B2 (en) 2017-03-09 2021-09-09 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitors
JP7096268B2 (ja) * 2017-05-01 2022-07-05 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤化合物の結晶形態
EP3609498A1 (en) * 2017-05-01 2020-02-19 Theravance Biopharma R&D IP, LLC Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
EP3713545A1 (en) 2017-11-22 2020-09-30 Dauntless 1, Inc. Therapeutic compound formulations
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
US10836763B2 (en) 2018-09-04 2020-11-17 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
AU2019335199A1 (en) * 2018-09-04 2021-03-11 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
JP7324836B2 (ja) 2018-09-04 2023-08-10 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としてのジメチルアミノアゼチジンアミド
KR20210084512A (ko) * 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
CN113316577A (zh) 2018-11-19 2021-08-27 纽约大学 作为治疗剂的GLi1抑制剂
HUE067145T2 (hu) * 2019-02-25 2024-10-28 Henan Medinno Pharmaceutical Tech Co Ltd JAK inhibitor vegyület és alkalmazása
CN114075200A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 用于治疗重症肺炎的jak抑制剂化合物
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021136345A1 (zh) * 2019-12-30 2021-07-08 路良 Jak抑制剂化合物及其用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2022178215A1 (en) 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
WO2022204473A1 (en) 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
JP2024524214A (ja) * 2021-06-25 2024-07-05 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としてのイミダゾロインダゾール化合物
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法
CN119403552A (zh) 2022-05-05 2025-02-07 施万生物制药研发Ip有限责任公司 用于通过雾化口腔吸入递送的奈珠西替尼

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039939A1 (en) * 2008-10-02 2010-04-08 Incyte Corporation Janus kinase inhibitors for treatment of dry eye and other eye related diseases
WO2013014567A1 (en) * 2011-07-27 2013-01-31 Pfizer Limited Indazoles
WO2014111380A1 (en) * 2013-01-17 2014-07-24 Galapagos Nv Novel compound useful for the treatment of degenerative and inflammatory diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
CA2673125C (en) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EP2288260A4 (en) 2008-06-20 2013-10-23 Genentech Inc TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
US20110184013A1 (en) 2008-10-01 2011-07-28 Shelley Allen Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
US20120029190A1 (en) 2009-04-03 2012-02-02 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CA2768543C (en) 2009-07-28 2017-06-20 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
NZ720092A (en) 2013-12-05 2019-05-31 Pfizer Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
CA2948587C (en) * 2014-05-14 2018-07-17 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
KR20180073687A (ko) 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
AU2018231035B2 (en) 2017-03-09 2021-09-09 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitors
EP3609498A1 (en) 2017-05-01 2020-02-19 Theravance Biopharma R&D IP, LLC Methods of treatment using a jak inhibitor compound
JP7096268B2 (ja) 2017-05-01 2022-07-05 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤化合物の結晶形態
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
JP7324836B2 (ja) 2018-09-04 2023-08-10 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としてのジメチルアミノアゼチジンアミド
US10836763B2 (en) 2018-09-04 2020-11-17 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
AU2019335199A1 (en) 2018-09-04 2021-03-11 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
WO2022204473A1 (en) 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039939A1 (en) * 2008-10-02 2010-04-08 Incyte Corporation Janus kinase inhibitors for treatment of dry eye and other eye related diseases
WO2013014567A1 (en) * 2011-07-27 2013-01-31 Pfizer Limited Indazoles
WO2014111380A1 (en) * 2013-01-17 2014-07-24 Galapagos Nv Novel compound useful for the treatment of degenerative and inflammatory diseases

Also Published As

Publication number Publication date
PH12018500828B1 (en) 2023-06-30
WO2017079205A1 (en) 2017-05-11
HK1252685A1 (zh) 2019-05-31
EA034914B1 (ru) 2020-04-06
JP2018531982A (ja) 2018-11-01
PH12018500828A1 (en) 2018-10-29
AU2016350816B2 (en) 2020-06-25
US20210130351A1 (en) 2021-05-06
CN108349972A (zh) 2018-07-31
SA518391470B1 (ar) 2021-03-31
US10913740B2 (en) 2021-02-09
US10100049B2 (en) 2018-10-16
US20170121327A1 (en) 2017-05-04
CA3001542C (en) 2021-02-16
MX2018005446A (es) 2018-08-01
US10183942B2 (en) 2019-01-22
BR112018008966B1 (pt) 2023-05-02
ZA201802496B (en) 2025-01-29
KR20180073687A (ko) 2018-07-02
CA3001542A1 (en) 2017-05-11
US20200087303A1 (en) 2020-03-19
EP3371186A1 (en) 2018-09-12
TWI710560B (zh) 2020-11-21
CO2018005640A2 (es) 2018-05-31
UA123633C2 (uk) 2021-05-05
NZ741737A (en) 2023-11-24
MY195427A (en) 2023-01-20
IL258772B (en) 2021-01-31
EA201891091A1 (ru) 2018-12-28
JP6800969B2 (ja) 2020-12-16
CL2018001145A1 (es) 2018-07-06
BR112018008966A2 (pt) 2018-11-27
MX374605B (es) 2025-03-06
US20220306624A1 (en) 2022-09-29
AU2016350816A1 (en) 2018-05-17
IL258772A (en) 2018-06-28
US10526330B2 (en) 2020-01-07
TW201726673A (zh) 2017-08-01
US20190106420A1 (en) 2019-04-11
US11718616B2 (en) 2023-08-08
US11299492B2 (en) 2022-04-12
US20180319796A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
CN108349972B (zh) 用于治疗呼吸疾病的jak激酶抑制剂化合物
EP3464245B1 (en) Benzazepine dicarboxamide compounds with tertiary amide function
CN111362975B (zh) 作为jak激酶抑制剂的萘啶化合物
CN103328472B (zh) 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶
EP3768272B1 (en) Jak inhibitors
CN112823037B (zh) 抑制去泛素化酶usp25和usp28
US8273890B2 (en) Thiophene-imidazopyridines
CN117098765A (zh) 作为詹纳斯激酶抑制剂的杂环衍生物
HK40085586B (zh) 哒嗪基噻唑甲酰胺类化合物
HK40059656B (zh) 哒嗪基噻唑甲酰胺类化合物
HK40002463A (en) Benzazepine dicarboxamide compounds with tertiary amide function

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210608